Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer in chemotherapy-naive patients: an Italian analysis of patients’ satisfaction

• Published in: Clinical genitourinary cancer Vol. 15; no. 5; pp. 520 - 525
• Main Authors: Cindolo, L, Natoli, C, De Nunzio, C, De Tursi, M, Valeriani, M, Giacinti, S, Micali, S, Rizzo, M, Bianchi, G, Martorana, E, Scarcia, M, Ludovico, G.M, Bove, P, Laudisi, A, Selvaggio, O, Carrieri, G, Bada, M, Castellan, P, Topazio, L, Boccasile, S, Ditonno, P, Chiodini, P, Schips, L
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2017
• Subjects: Abiraterone acetate; Abiraterone Acetate - administration & dosage; Abiraterone Acetate - therapeutic use; Aged; Aged, 80 and over; Androgen deprivation therapy; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - therapeutic use; Castration-resistant prostate cancer; Disease Progression; Disease-Free Survival; Hematology, Oncology and Palliative Medicine; Humans; Male; Metastatic prostate cancer; Patient reported outcomes; Patient Satisfaction; Prostate-Specific Antigen - metabolism; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - metabolism; Quality of Life; Retrospective Studies; Treatment Outcome; Urology; Patient Reported Outcomes; Pattern-mixture model; castration-resistant prostate cancer; PCa; mCRPC; SD; Progression free survival; Mixed-effects model for repeated measures; HRQoL; Standard deviation; PFS; HRPC; androgen deprivation therapy; AA; Health-related quality of life; PROs; OR; OS; CI; metastatic castration-resistant prostate cancer; Hormone-resistant prostate cancer; Confidence interval; patient satisfaction; AR; PMM; Overall Survival; Odds ratio; abiraterone acetate; Androgen-receptor; Prostate cancer; MMRM; Castration-resistant prostate cancer; Metastatic prostate cancer; Androgen deprivation therapy; Abiraterone acetate; Patient reported outcomes
• ISSN: 1558-7673; 1938-0682
• DOI: 10.1016/j.clgc.2017.04.003

Abstract Introduction Abiraterone acetate (AA) gives a significant improvement in survival for patients with metastatic castration-resistant prostate cancer (mCRPC) before and after chemotherapy and has a favourable impact on patients’ health-related quality of life and pain. Only few papers have investigated Patient Reported Outcomes (PROs) in AA treatment for mCRPC. Aim of this study was to investigate patients’ satisfaction in men affected by mCRPC under AA. Materials & Methods Retrospective analysis of a database of consecutive chemonaive patients with progressive mCRPC. Patients were treated with AA until disease progression, death or unacceptable toxicity. Evaluation was performed at baseline and every 4 weeks by means of physical examination and laboratory studies. ECOG score, pain symptoms, treatment-related toxicity, PSA, overall and progression-free survival were recorded. Satisfaction on treatment was investigated at 6 months by means of a 4-point arbitrary scale. Results One-hundred twenty eight patients were enrolled. Patients’ satisfaction on treatment was “greatly improved” in 36.1% of patients and “improved” in 32.4% of them. Patients with higher satisfaction had lower baseline and final PSA values (p<0.05), lower PSA at 12 weeks (p=0,080) and less pain symptoms and lower Brief Pain Inventory score (p=0,001). Satisfaction on treatment was significantly correlated with baseline PSA (p=0,018), presence of pain (p=0,007), duration of ADT >12months (p=0,025), and number of hormonal manipulations (p=0,051). Progression free survival significantly correlated with patient satisfaction (p<0.001). Conclusion AA is safe and well tolerated in chemonaive mCRPC patients, ensures good oncological and PRO outcomes. Patient’s satisfaction is a predictor of progression free survival.